本文選題：肝豆狀核變性 + 肝纖維化�。� 參考：《實用醫(yī)學(xué)雜志》2015年19期

【摘要】：目的:探討骨髓間充質(zhì)干細胞(BMSCs)對肝豆狀核變性肝纖維化患者的治療作用。方法 :60例確診肝豆狀核變性肝纖維化患者,隨機分為3組:青霉胺組、BMSCs組和BMSCs+青霉胺組,口服青霉胺劑量為每日40 mg/kg,將采集的BMSCs液2 m L+生理鹽水100 m L經(jīng)靜脈輸注入人體。分別于治療前后做肝組織病理活檢,檢測0、4、8、12周血清透明質(zhì)酸(HA)、Ⅲ型前膠原(PCⅢ)、層黏蛋白(LN)、Ⅳ型膠原(CⅣ)、基質(zhì)金屬蛋白酶-1(MMP-1)、基質(zhì)金屬蛋白酶抑制劑-1(TIMP-1)的變化。結(jié)果:BMSCs+青霉胺組肝組織活檢肝纖維化明顯改善;各組血清中HA、PCⅢ、LN、CⅣ、TIMP-1、MMP-1均持續(xù)降低,BMSCs+青霉胺組血清中各細胞因子的改善比其他組明顯,差異具有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:BMSCs聯(lián)合青霉胺治療肝豆狀核變性合并肝纖維化有明顯改善作用。
[Abstract]:Objective: to investigate the therapeutic effect of bone marrow mesenchymal stem cells (BMSCs) on hepatic fibrosis of hepatolenticular degeneration. Methods 60 patients with liver fibrosis were randomly divided into three groups: penicillamine group and BMSCs penicillamine group. The oral dose of penicillamine was 40 mg / kg daily. The collected BMSCs solution of 2 mL normal saline was injected intravenously into human body. The changes of serum hyaluronic acid (HA), type 鈪，

本文編號：1862033